NTRB NASDAQ
Orlando, FL 32801
US
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Sheridan Gareth | 0 | — | 2025-01-31 | |
| Sheridan Gareth | A-Award | 29,333 | $8.07 | 2025-01-29 |
| Goodman Gerald | A-Award | 17,667 | $7.34 | 2025-01-23 |
| Goodman Gerald | M-Exempt | 87,500 | $1.93 | 2024-06-06 |
| Goodman Gerald | X-InTheMoney | 60,085 | $1.93 | 2024-06-05 |